Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa
29. November 2021 07:00 ET
|
Krystal Biotech, Inc.
• Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints, and its secondary endpoint of complete wound healing at three-month timepoints VYJUVEKTM was well...
Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress
08. November 2021 07:00 ET
|
Krystal Biotech, Inc.
– Top-line results from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) on track for 4Q21 – Enrollment in Phase 1 proof-of-concept study (PEARL-1 study) to treat...
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
26. Oktober 2021 07:00 ET
|
Krystal Biotech, Inc.
Topline results anticipated in the fourth quarter of 2021Of the 31 patients enrolled in the trial, 29 patients completed the study with no missing visits, including the three primary endpoint...
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis
19. Oktober 2021 16:05 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the presentation of...
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT
14. Oktober 2021 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present...
Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference
01. Oktober 2021 16:01 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced its participation in the...
Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis
29. September 2021 08:00 ET
|
Krystal Biotech, Inc.
- KB407 is an investigational inhaled gene therapy derived from Krystal’s clinically validated redosable gene delivery technology platform PITTSBURGH, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Krystal...
Krystal Biotech Appoints Laurent Goux as General Manager of Europe
15. September 2021 08:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the appointment of Laurent...
Krystal Biotech to Present Data on DEB and B-VEC at the DEBRA International Conference 2021
09. September 2021 08:00 ET
|
Krystal Biotech, Inc.
Data include evaluation of investigational B-VEC in a murine corneal wound modelU.S. FDA has recently approved a compassionate use request for topical B-VEC application to one eye in a RDEB patient ...
Krystal Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
07. September 2021 16:31 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it will be featured as a...